An Independent Data Monitoring Committee (IDMC) recommended AbbVie terminate their Rova-T research and development programme, based on results at interim analysis showing a lack of survival benefit compared with the placebo control arm.
Rova-T was being evaluated within the study as a first line maintenance therapy for advanced small-cell lung cancer (SCLC). AbbVie has already incurred an impairment charge of $4 billion earlier in the year following a previous trail failure.
“AbbVie Announces the Discontinuation of Rova-T“
“We’re disappointed with the outcome of this trail,” said Margaret Foley, vice president, global head of tumour development at AbbVie. “SCLC continues to be one of the most difficult to treat cancers, and we remain committed to researching and developing other therapies that have the potential to transform care for patients.”